One page, thousands of outlets. See who else covered it.
John Loos, independent economist, discuss the impending PIC transaction, building cycle since COVID-19 pandemic and Balwin’s tenure at the JSE as it prepares to delist.
We haven't written up this one. Moneyweb has the full story — the link below goes straight to it.
The deal gives BioMarin access to ALE1, a small-molecule drug in early-stage trials that could become the first oral therapy for hypophosphatasia
Roland Busch replies to emails with ‘OK’ or ‘No’ and refuses to hold recurring one-on-ones. He’s not the only CEO cutting the fat.
Roland Busch replies to emails with “OK” or “No” and refuses to hold recurring one-on-ones. He’s not the only CEO cutting the fat.
Seel, an AI-driven operations platform for commerce, today launched a new resale capability within its order center that allows shoppers to recover value from their gently used clothes when they’re no…
Robust compensation and metering, along with strong customer protections, are needed to drive participation in utility virtual power plants programs, according to experts.
